The immunomodulatory molecule and co-inhibitory receptor T cell immunoreceptor with Ig and ITIM domains (TIGIT) could be used to treat autoimmune diseases, according to results in a mouse model of lupus. Treatment of NZB/W F1 mice with a TIGIT-Ig fusion protein inhibited production of anti-double-stranded-DNA antibodies, delayed the development of proteinuria and prolonged survival in comparison with mice treated with control IgG. The TIGIT-Ig fusion protein demonstrated IgG-like stability similar to that of CTLA-4-Ig.
References
Original article
Liu, S. et al. Treatment of murine lupus with TIGIT-Ig. Clin. Immunol. https://doi.org/10.1016/j.clim.2019.04.007 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Onuora, S. TIGIT-Ig shows therapeutic potential in SLE. Nat Rev Rheumatol 15, 318 (2019). https://doi.org/10.1038/s41584-019-0230-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0230-x